Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of three treatment strategies in IgG4-RD patients with superficial organ involvement: Diprospan plus iguratimod, Diprospan plus leflunomide and prednisone plus leflunomide.
Epistemonikos ID: 649912c72955223b9ffc3a5e69ad982135a9e8c8
First added on: Feb 19, 2024